Syndax Pharmaceuticals, Inc. (SNDX) Bundle
An Overview of Syndax Pharmaceuticals, Inc. (SNDX)
General Summary of Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for cancer and other serious diseases. Founded in 2005 and headquartered in Waltham, Massachusetts.
- Primary focus areas: Oncology and immuno-oncology
- Key product: Entinostat (SNDX-275)
- Public trading: NASDAQ under ticker SNDX
Financial Performance (Q4 2023 and Full Year 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $44.3 million |
| Net Loss | $127.2 million |
| Cash and Investments | $345.6 million |
| Research and Development Expenses | $98.7 million |
Company Leadership in Oncology Market
Syndax Pharmaceuticals specializes in developing innovative cancer therapies, with a strong pipeline of potential treatments targeting multiple cancer types.
- Lead clinical programs: Axatilimab and entinostat
- Ongoing clinical trials in multiple oncology indications
- Strategic collaborations with major pharmaceutical companies
| Clinical Pipeline Status | Details |
|---|---|
| Active Clinical Trials | 7 ongoing trials |
| Primary Research Focus | Solid tumors and hematologic malignancies |
Mission Statement of Syndax Pharmaceuticals, Inc. (SNDX)
Mission Statement of Syndax Pharmaceuticals, Inc. (SNDX)
Syndax Pharmaceuticals, Inc. mission statement focuses on advancing targeted therapies for patients with cancer and other challenging diseases.
Core Components of Mission Statement
| Component | Specific Details |
|---|---|
| Therapeutic Focus | Precision oncology and epigenetic therapies |
| Research Priority | Developing innovative targeted treatment approaches |
| Patient Impact | Improving clinical outcomes for cancer patients |
Key Research Priorities
- Developing entinostat as potential combination therapy
- Advancing HDAC inhibitor technologies
- Targeting specific molecular pathways in oncology
Research Pipeline Statistics
| Program | Clinical Stage | Target Indication |
|---|---|---|
| Entinostat | Phase 3 | Advanced Breast Cancer |
| SNDX-5613 | Phase 1/2 | MLL Leukemia |
Financial Investment in Research
R&D Expenditure in 2023: $83.4 million
Clinical Development Focus
- Precision oncology therapeutics
- Epigenetic modulation strategies
- Targeted molecular interventions
Market Capitalization as of 2024: $456.2 million
Vision Statement of Syndax Pharmaceuticals, Inc. (SNDX)
Vision Statement of Syndax Pharmaceuticals, Inc. (SNDX)
Therapeutic Focus and Strategic DirectionSyndax Pharmaceuticals, Inc. centers its vision on developing innovative precision oncology and immuno-oncology therapies targeting critical unmet medical needs.
| Key Vision Components | Specific Details |
|---|---|
| Primary Research Areas | Solid tumors, hematologic malignancies |
| Key Therapeutic Platforms | Epigenetic therapies, immunotherapy |
| R&D Investment (2023) | $83.4 million |
- Develop targeted therapies with molecular precision
- Advance clinical-stage oncology programs
- Explore combination treatment approaches
| Drug Candidate | Indication | Clinical Stage |
|---|---|---|
| Entinostat | Advanced Solid Tumors | Phase 2/3 |
| SNDX-5613 | MLL Rearranged Leukemia | Phase 1/2 |
As of Q4 2023, Syndax maintained $362.1 million in cash and cash equivalents, supporting continued research and development initiatives.
Core Values of Syndax Pharmaceuticals, Inc. (SNDX)
Core Values of Syndax Pharmaceuticals, Inc. (SNDX)
Innovation and Scientific Excellence
Syndax Pharmaceuticals demonstrates commitment to innovation through its research and development efforts.
| R&D Investment (2023) | Number of Active Clinical Trials |
|---|---|
| $98.4 million | 7 ongoing clinical trials |
- Focus on precision oncology and epigenetic therapies
- Developed entinostat as a potential combination therapy
- Maintained 12 active research programs in 2023
Patient-Centered Approach
Commitment to improving patient outcomes through targeted therapeutic solutions.
| Patient Enrollment (2023) | Clinical Trial Diversity Initiatives |
|---|---|
| Over 250 patients in clinical studies | 3 dedicated diversity recruitment programs |
Collaborative Research and Partnerships
Strategic collaborations to advance scientific research and drug development.
| Active Research Partnerships | Collaborative Research Funding |
|---|---|
| 5 academic and pharmaceutical partnerships | $22.3 million in collaborative research grants |
- Partnerships with MD Anderson Cancer Center
- Collaborative research with Memorial Sloan Kettering
- Strategic alliance with Merck & Co.
Ethical and Transparent Operations
Maintaining highest standards of corporate governance and research integrity.
| Corporate Governance Ratings | Compliance Investments |
|---|---|
| ISS ESG Rating: B | $3.2 million in compliance infrastructure |
Sustainability and Environmental Responsibility
Commitment to sustainable research practices and environmental consciousness.
| Carbon Footprint Reduction | Sustainable Research Initiatives |
|---|---|
| 17% reduction in laboratory waste | 2 green chemistry research programs |
Syndax Pharmaceuticals, Inc. (SNDX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.